InvestSMART

4DMedical Limited (ASX: 4DX) - Announcements

Current share price for 4DX : $4.310 0.51 (13.42%)+

ASX company news and announcements for 4DMedical Limited (4DX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All 4DMedical Limited (4DX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than 4DMedical Limited (4DX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for 4DMedical Limited (4DX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,593 Becoming a substantial holder 12 Mar 2021 5:05PM $1.500 $4.310 risen by 187.33%
$2,593 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $1.500 $4.310 risen by 187.33%
$2,593 Appendix 2A 11 Mar 2021 11:22AM $1.545 $4.310 risen by 178.96%
$2,593 Cleansing Notice 11 Mar 2021 11:12AM $1.555 $4.310 risen by 177.17%
$2,593 Proposed issue of Securities - 4DX 4 Mar 2021 8:55AM $1.730 $4.310 risen by 149.13%
$2,593 Award of MRFF Frontier grant & capital raising presentation 4 Mar 2021 8:55AM $1.730 $4.310 risen by 149.13%
$2,593 Reinstatement to Official Quotation 4 Mar 2021 8:52AM $1.730 $4.310 risen by 149.13%
$2,593 4DMedical successfully completes A$40m placement 4 Mar 2021 8:51AM $1.730 $4.310 risen by 149.13%
$2,593 4DMedical-led consortium awarded $28.9m MRFF grant 2 Mar 2021 9:20AM $1.730 $4.310 risen by 149.13%
$2,593 Voluntary Suspension 2 Mar 2021 9:13AM $1.730 $4.310 risen by 149.13%
$2,593 Trading Halt 26 Feb 2021 8:45AM $1.730 $4.310 risen by 149.13%
$2,593 4DMedical reports 1H FY21 results 25 Feb 2021 8:07AM $1.700 $4.310 risen by 153.53%
$2,593 Appendix 4D and Half-Year Financial Report 25 Feb 2021 8:06AM $1.700 $4.310 risen by 153.53%
$2,593 Appointment of Chief Information Officer 18 Feb 2021 9:44AM $1.950 $4.310 risen by 121.03%
$2,593 Appendix 2A 5 Feb 2021 11:21AM $2.120 $4.310 risen by 103.30%
$2,593 Release of restricted securities from escrow 5 Feb 2021 11:18AM $2.110 $4.310 risen by 104.27%
$2,593 Quarterly Activity Report and Appendix 4C for Q2 FY202 28 Jan 2021 8:32AM $2.250 $4.310 risen by 91.56%
$2,593 First U.S. clinical pilot for XV LVAS at St. Joseph Hospital 27 Jan 2021 8:26AM $2.260 $4.310 risen by 90.71%
$2,593 Release of restricted securities from escrow 21 Dec 2020 1:36PM $2.270 $4.310 risen by 89.87%
$2,593 4DMedical completes first commercial scan in Australia 18 Dec 2020 9:09AM $2.110 $4.310 risen by 104.27%
$2,593 S&P DJI Announces December 2020 Quarterly Rebalance 11 Dec 2020 5:10PM $2.150 $4.310 risen by 100.47%
$2,593 Ceasing to be a substantial holder 11 Dec 2020 4:35PM $2.150 $4.310 risen by 100.47%
$2,593 Appendix 2A 10 Dec 2020 2:40PM $2.230 $4.310 risen by 93.27%
$2,593 Release of restricted securities from escrow 10 Dec 2020 2:35PM $2.230 $4.310 risen by 93.27%
$2,593 Research program with University of Miami Health System 2 Dec 2020 8:53AM $2.350 $4.310 risen by 83.40%

526 - 550 of 597 results

Page 22 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.